2022 Otto Bayer Award goes to Professor Frank Glorius
- Details
- Category: Bayer

Pfizer reports record full-year 2022 results
- Details
- Category: Pfizer

AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
- Details
- Category: Amgen

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
- Details
- Category: Bayer

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- Details
- Category: Roche

Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
- Details
- Category: Pfizer

Acquisition of Neogene Therapeutics completed
- Details
- Category: AstraZeneca

Neogene will operate as a wholly owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands and California, US.
More Pharma News ...
- Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
- NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs
- AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline
- Pfizer announces positive top-line results from Phase 3 study of hemophilia B gene therapy candidate
- VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
- Pfizer announces FDA and EMA acceptance of etrasimod regulatory submissions for ulcerative colitis
- Recombinant adeno-associated virus (rAAV) technology pioneered by AskBio's Dr. Jude Samulski is key component of all FDA approved AAV gene therapeutics